
Sylentis’ pipeline is directed towards indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases.
********************

ECCO : EUROPEAN CROHN,S AND COLITIS ORGANISATION .
PHARMAMAR HA OPTADO POR LA RETIRADA DE LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN DE APLIDIN ( PLITIDEPSIN ) ... WITHDRAWAL OF APPLICATIÓN FOR THE MARKETING AUTHORISATION OF APLIDIN ( PLITIDEPSIN ) JULY 23 , 2025 .